Charlie Gayer: Yes. So the basic €“ the essence of that was we expanded the number of sales regions. It was not a major sales force expansion, but we made our regions smaller. So, added more regional managers so that they can work closely with their teams as well as some of the top KOLs. Then simultaneously, we also added more to our market access team and our patient access specialist team so that we can do more to work with customers and particularly patients who help to get paid therapy.
Liisa Bayko: Okay, thanks. And then just a follow-up to Chris’ question, are you €“ when will you get €“ when are you going to complete this preclinical tox study?
Jon Stonehouse: It will be sometime this year.
Liisa Bayko: Okay. And any sense do you think this might be something specific to the species and like what species have you been looking at?
Jon Stonehouse: That’s a really good question that we don’t have an answer to.
Liisa Bayko: Okay. Can you mention the species just for
Jon Stonehouse: Yes. Not at this time, no.
Liisa Bayko: Okay. Okay. And then just final question for me, are you able to get clinically into what you think is an efficacious dose range or as you described going more slowly now in kind of your dose escalation, are you going to be kind of capped below what you think is the target efficacious dose?
Jon Stonehouse: Our hope is that we get to an effective dose in the safe range I don’t think we can answer that question today, given what we’re seeing, but that’s the whole.
Helen Thackray: And I would add, we already know from the data that we presented in January excellent pressure of the alternative pathway complement of 24 hours already with the dose has been evaluating volunteers. So we have more to learn about the range that information.
Liisa Bayko: Okay, thank you.
Jon Stonehouse: Welcome.
Operator: The next question comes from Jon Wolleben of JMP Securities. Please go ahead.
Jon Wolleben: Hey, thanks for taking the question. Just a couple on ORLADEYO, I wonder if you could tell us what the quarter-over-quarter patient growth was in fourth quarter. And then with regards to the $320 million guidance, what’s the breakdown between U.S. and ex U.S. contribution there?
Anthony Doyle: Sure, Jon. We haven’t specified the growth. What I can say is we are on the same trends, both in terms of new patient acquisition that we’ve seen over the last many quarters. And also our discontinuation rate has been very stable. So what that means is that every quarter, we’re growing nicely, and that would that’s what gives us so much confidence in the $320 million this year and the long-term projection to $1 billion. And €“ you want to add something.
Charlie Gayer: Yes, I think in terms of contribution from €“ the way I think about it, John, is U.S. continues to be the majority of revenue. When we get to a point, and we will get to a point, hopefully, where we will split out U.S. and ex U.S. That will be when ex U.S. accounts for around 10% of total revenue. When that will be will be. But at the moment, I think we’re doing really well in both the U.S. and from a global expansion.
Jon Wolleben: Very helpful. Thank you.
Operator: The next question comes from Ken Cacciatore of Cowen & Company. Please go ahead.
